François-Clément Bidard, Vice President – French Breast Cancer Group at Unicancer, shared on LinkedIn:
“T-DXd is now available in France as a rescue post-neoadjuvant therapy (per DB-05).
For HER2-positive eBC – no pCR and ypN+ or no pCR in breast and initially cT4 or cN2-3.
Great news for ypN+ patients, while discussions will likely continue for the ypN0 population.”
Other articles about breast cancer on OncoDaily.